Ligand id: 6360

Name: lisinopril

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: lisinopril

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 132.96
Molecular weight 405.23
XLogP 1.11
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Competitive inhibitor of ACE used to treat hypertension and congestive heart failure. An orally administered lisinopril solution (Qbrelis) is FDA approved (August 2016), and can be used for managing hypertension in adults and children 6 years of age and older.
Mechanism Of Action and Pharmacodynamic Effects
Binds to angeotensin-converting enzyme and thereby competes with the binding of angiotensin I, inhibiting its conversion to angiotensin II. The resulting decreased levels of angiotensin II leads to decreased blood pressure and an increase in plama renin activity.